Project: Development of a novel nasal therapy containing antimicrobial peptides to treat MRSA carriage

The aim of this project is to develop a nasal therapy with antimicrobial peptides (AMPs) to eradicate MRSA carriage. The synthetic AMPs that were previously developed by Madam Therapeutics (Madam) and Leiden University Medical Center (LUMC) have shown to be fully effective against antibiotic-resistant bacterial strains in in vitro models, including MRSA. At the end of this project, an AMP-based nasal therapy will be available, with associated Proof-of-Mechanism and safety data package.

Acronym NAS-AMP (Reference Number: 9795)
Duration 01/01/2016 - 01/01/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 3

Project partner

Number Name Role Country
21779 Madam Therapeutics B.V. Coordinator Netherlands
21780 Leids Universitair Medisch Centrum Partner Netherlands
21781 SISAF Ltd Partner United Kingdom
21782 "Toxi-Coop" Toxicological Research Center Zrt Partner Hungary